Moreover, the combination of these biomarkers might also be used to follow the progression of the disease severity from pulmonary involvement (serum NSE) to the enhanced systemic inflammation (gut permeability defect and NETosis) and/or the progression into sepsis (presepsin). The gene discussed is ENO2; the disease is Sepsis.